<DOC>
	<DOCNO>NCT01810276</DOCNO>
	<brief_summary>The objective study determine administration platelet improve outcome patient ICH treat either aspirin , thienopyridine ( ticlodipine , clopidogrel , prasugrel ) combination . The study four specific aim : 1 . To determine affect platelet administration bleed brain . 2 . To determine affect platelet administration brain function . Several assessment test function brain perform enrollment throughout study . Comparing result assessment experimental control group allow u determine platelet administration improve outcomes patient bleed brain expose antiplatelet therapy . 3 . An important risk reverse antiplatelet therapy expose patient complication therapy design prevent . Therefore , track complication important part study . The investigator compare rate death , heart attack , stroke clot vein group . 4 . Some patient ( 10-40 % ) limit responsiveness antiplatelet therapy . While platelet responsiveness , measure special platelet blood test , affect enrollment , investigator feel important measure .</brief_summary>
	<brief_title>Safety Platelet Transfusion Patients Antiplatelet Therapy With Traumatic Head Injury</brief_title>
	<detailed_description>Intracranial hemorrhage ( ICH ) , bleed brain , major cause death trauma patient . The initial volume early growth hematoma critical determinant mortality functional outcome . As population age , significant grow number patient present ICH antiplatelet therapy . Bleeding well know complication therapy . It likely patient ICH expose antiplatelet therapy would increase risk hemorrhage growth poor outcome compare patient use antiplatelet therapy . There pharmacologic agent reverse antithrombotic effect aspirin thienopyridines . There paucity publish data , one small phase one trial two retrospective study address use platelet mean reverse effect antiplatelet therapy patient suffer ICH . In addition , transfusion platelet may associate transfusion reaction , infection fluid overload . Furthermore , patient expose thromboembolic complication antiplatelet therapy design prevent . Given lack data , primarily retrospective likely underpowered , The investigator feel 's important conduct trial definitively study efficacy antiplatelet reversal patient life threaten ICH . Furthermore , would important understand , benefit antiplatelet reversal patient ICH , benefit outweigh risk antiplatelet reversal .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Craniocerebral Trauma</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Intracranial Hemorrhage , Traumatic</mesh_term>
	<criteria>18 year old Evidence intracranial hemorrhage ( bleed brain ) CT scan relate traumatic injury Receiving antiplatelet therapy aspirin , thienopyridine ( ticlopidine , clopidogrel , prasugrel ) Platelet count great equal 100,000 Glasgow Coma Scale ( GCS ) less 6 Hemorrhage require emergent surgery Lack permission treat physician and/or consultant Secondary ICH relate aneurysm arteriovenous malformation Use oral anticoagulant Decreased platelet ( thrombocytopenia ) Patients require massive transfusion protocol Life expectancy le 3 month Confirmed acute heart attack Hepatitis liver cirrhosis Kidney failure Participation another treatment study within precede 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>traumatic head injury</keyword>
	<keyword>intracranial hemorrhage</keyword>
	<keyword>platelet</keyword>
	<keyword>anti-platelet therapy</keyword>
	<keyword>plavix</keyword>
	<keyword>asprin</keyword>
</DOC>